viewAminex PLC

Aminex extends long-stop for Ruvuma farm-out transaction by two weeks

The farm-out is expected to complete soon and resulting funds should cover the company financially until May 2021

Aminex PLC - Aminex extends long-stop for Ruvuma transaction by two weeks

Aminex PLC (LON:AEX) told investors that the long stop date in the Ruvuma farm-out transaction has been further extended, and it now has an extra fortnight to close the transaction – with the new date set as July 31.

At the same time, Aminex detailed some additional cost-saving measures including the waiving and surrendering of rights to director share options. There are also proposals, set out a week ago, which will see key employees sacrifice salary in return for share options. The moves aim to reduce the group's overhead and are subject to shareholder approval

READ: Aminex set to complete pivotal farm-out

Aminex added that it is exercising very tight control over costs. Payments related to the farm-out are expected to fund the company until around May 2021, according to the group's management.

"With these cost reduction initiatives, the expected completion of the farm-out soon, and the continued support of ARA and Eclipse, our cornerstone investor, the company looks forward to its next stage of development," Aminex chief executive Robert Ambrose said in a statement released after the London market close on Tuesday.

Quick facts: Aminex PLC

Price: 1.025 GBX

Market: LSE
Market Cap: £38.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aminex PLC named herein, including the promotion by the Company of Aminex PLC in any Content on the Site, the Company receives from said issuer...


Market Report: FTSE gets an injection of optimism from US Remdesivir approval

FTSE 100 got a lift as a first treatment for COVID-19, remdesivir, was approved in the US. London’s leading index added 41 points to 5,826 in early dealings. Gilead Inc (NASDAQ:GILD) produces remdesivir and it is said to cut COVID-19 recovery times by five days. According to the World Health...

1 week, 1 day ago

2 min read